Prognostic factors for patients with bone-only metastasis in breast cancer

Sung Gwe Ahn, Hak Min Lee, Sang Hoon Cho, Seung Ah Lee, Seung Hyun Hwang, Jeong Joon, Hy De Lee

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Purpose: Bone is the most frequent site of metastasis among breast cancer patients. We investigated prognostic factors affecting survival following bone-only metastasis in breast cancer patients. Materials and Methods: The medical records of breast cancer patients who were treated and followed at Gangnam Severance Hospital retrospectively reviewed to identify patients with bone-only metastasis. Results: The median time from the diagnosis of bone-only metastasis to the last follow-up or death was 55.2 [95% confidence interval (CI), 38.6-71.9] months. The Kaplan-Meier overall survival estimate at 10 years for all patients was 34.9%. In the multivariate Cox regression model, bisphosphonate treatment [hazard ratio=0.18; 95% CI, 0.07-0.43], estrogen receptor positivity (hazard ratio=0.51; 95% CI, 0.28-0.94), and solitary bone metastasis (hazard ratio=0.32; 95% CI, 0.14-0.72) were significantly associated with longer overall survival in the bone-only recurrence group. Among the treatment modalities, only bisphosphonate treatment was identified as a significant prognostic factor. Conclusion: Identifying the factors influencing breast cancer mortality after bone-only metastasis will help clarify the clinical course and improve the treatment outcome for patients with breast cancer and bone-only metastasis. Bisphosphonates, as a significant prognostic factor, warrant further investigation.

Original languageEnglish
Pages (from-to)1168-1177
Number of pages10
JournalYonsei medical journal
Volume54
Issue number5
DOIs
Publication statusPublished - 2013 Sep 1

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Diphosphonates
Confidence Intervals
Survival
Bone Neoplasms
Proportional Hazards Models
Estrogen Receptors
Medical Records
Therapeutics
Recurrence
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Ahn, S. G., Lee, H. M., Cho, S. H., Lee, S. A., Hwang, S. H., Joon, J., & Lee, H. D. (2013). Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei medical journal, 54(5), 1168-1177. https://doi.org/10.3349/ymj.2013.54.5.1168
Ahn, Sung Gwe ; Lee, Hak Min ; Cho, Sang Hoon ; Lee, Seung Ah ; Hwang, Seung Hyun ; Joon, Jeong ; Lee, Hy De. / Prognostic factors for patients with bone-only metastasis in breast cancer. In: Yonsei medical journal. 2013 ; Vol. 54, No. 5. pp. 1168-1177.
@article{d31b0be0170d454bacf35f7010b7a860,
title = "Prognostic factors for patients with bone-only metastasis in breast cancer",
abstract = "Purpose: Bone is the most frequent site of metastasis among breast cancer patients. We investigated prognostic factors affecting survival following bone-only metastasis in breast cancer patients. Materials and Methods: The medical records of breast cancer patients who were treated and followed at Gangnam Severance Hospital retrospectively reviewed to identify patients with bone-only metastasis. Results: The median time from the diagnosis of bone-only metastasis to the last follow-up or death was 55.2 [95{\%} confidence interval (CI), 38.6-71.9] months. The Kaplan-Meier overall survival estimate at 10 years for all patients was 34.9{\%}. In the multivariate Cox regression model, bisphosphonate treatment [hazard ratio=0.18; 95{\%} CI, 0.07-0.43], estrogen receptor positivity (hazard ratio=0.51; 95{\%} CI, 0.28-0.94), and solitary bone metastasis (hazard ratio=0.32; 95{\%} CI, 0.14-0.72) were significantly associated with longer overall survival in the bone-only recurrence group. Among the treatment modalities, only bisphosphonate treatment was identified as a significant prognostic factor. Conclusion: Identifying the factors influencing breast cancer mortality after bone-only metastasis will help clarify the clinical course and improve the treatment outcome for patients with breast cancer and bone-only metastasis. Bisphosphonates, as a significant prognostic factor, warrant further investigation.",
author = "Ahn, {Sung Gwe} and Lee, {Hak Min} and Cho, {Sang Hoon} and Lee, {Seung Ah} and Hwang, {Seung Hyun} and Jeong Joon and Lee, {Hy De}",
year = "2013",
month = "9",
day = "1",
doi = "10.3349/ymj.2013.54.5.1168",
language = "English",
volume = "54",
pages = "1168--1177",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "5",

}

Ahn, SG, Lee, HM, Cho, SH, Lee, SA, Hwang, SH, Joon, J & Lee, HD 2013, 'Prognostic factors for patients with bone-only metastasis in breast cancer', Yonsei medical journal, vol. 54, no. 5, pp. 1168-1177. https://doi.org/10.3349/ymj.2013.54.5.1168

Prognostic factors for patients with bone-only metastasis in breast cancer. / Ahn, Sung Gwe; Lee, Hak Min; Cho, Sang Hoon; Lee, Seung Ah; Hwang, Seung Hyun; Joon, Jeong; Lee, Hy De.

In: Yonsei medical journal, Vol. 54, No. 5, 01.09.2013, p. 1168-1177.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic factors for patients with bone-only metastasis in breast cancer

AU - Ahn, Sung Gwe

AU - Lee, Hak Min

AU - Cho, Sang Hoon

AU - Lee, Seung Ah

AU - Hwang, Seung Hyun

AU - Joon, Jeong

AU - Lee, Hy De

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Purpose: Bone is the most frequent site of metastasis among breast cancer patients. We investigated prognostic factors affecting survival following bone-only metastasis in breast cancer patients. Materials and Methods: The medical records of breast cancer patients who were treated and followed at Gangnam Severance Hospital retrospectively reviewed to identify patients with bone-only metastasis. Results: The median time from the diagnosis of bone-only metastasis to the last follow-up or death was 55.2 [95% confidence interval (CI), 38.6-71.9] months. The Kaplan-Meier overall survival estimate at 10 years for all patients was 34.9%. In the multivariate Cox regression model, bisphosphonate treatment [hazard ratio=0.18; 95% CI, 0.07-0.43], estrogen receptor positivity (hazard ratio=0.51; 95% CI, 0.28-0.94), and solitary bone metastasis (hazard ratio=0.32; 95% CI, 0.14-0.72) were significantly associated with longer overall survival in the bone-only recurrence group. Among the treatment modalities, only bisphosphonate treatment was identified as a significant prognostic factor. Conclusion: Identifying the factors influencing breast cancer mortality after bone-only metastasis will help clarify the clinical course and improve the treatment outcome for patients with breast cancer and bone-only metastasis. Bisphosphonates, as a significant prognostic factor, warrant further investigation.

AB - Purpose: Bone is the most frequent site of metastasis among breast cancer patients. We investigated prognostic factors affecting survival following bone-only metastasis in breast cancer patients. Materials and Methods: The medical records of breast cancer patients who were treated and followed at Gangnam Severance Hospital retrospectively reviewed to identify patients with bone-only metastasis. Results: The median time from the diagnosis of bone-only metastasis to the last follow-up or death was 55.2 [95% confidence interval (CI), 38.6-71.9] months. The Kaplan-Meier overall survival estimate at 10 years for all patients was 34.9%. In the multivariate Cox regression model, bisphosphonate treatment [hazard ratio=0.18; 95% CI, 0.07-0.43], estrogen receptor positivity (hazard ratio=0.51; 95% CI, 0.28-0.94), and solitary bone metastasis (hazard ratio=0.32; 95% CI, 0.14-0.72) were significantly associated with longer overall survival in the bone-only recurrence group. Among the treatment modalities, only bisphosphonate treatment was identified as a significant prognostic factor. Conclusion: Identifying the factors influencing breast cancer mortality after bone-only metastasis will help clarify the clinical course and improve the treatment outcome for patients with breast cancer and bone-only metastasis. Bisphosphonates, as a significant prognostic factor, warrant further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84880976794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880976794&partnerID=8YFLogxK

U2 - 10.3349/ymj.2013.54.5.1168

DO - 10.3349/ymj.2013.54.5.1168

M3 - Article

VL - 54

SP - 1168

EP - 1177

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 5

ER -